In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent ...
EBS) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short. Based on the recent average volume of 1.40M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback